The role of natriuretic peptides in inflammation and immunity

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 4, Issue 2, 2010, Pages 90-104

  Casserly, Brian P ^a   Sears, Edmund H ^a   Gartman, Eric J ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Immune system; Inflammation; Natriuretic peptides; Therapeutics

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; INTERLEUKIN 12; MACROGOL; NATRIURETIC PEPTIDE TYPE C;

ADAPTIVE IMMUNITY; ALLERGIC DISEASE; ARTICLE; BINDING AFFINITY; CELL MEMBRANE PERMEABILITY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG ACTIVITY; ENDOTHELIUM CELL; HEART ATRIUM FIBRILLATION; HUMAN; IMMUNE SYSTEM; IMMUNITY; INFLAMMATION; INNATE IMMUNITY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; NATURAL KILLER CELL; NONHUMAN; OXIDATIVE STRESS; PERMEABILITY BARRIER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; T LYMPHOCYTE; TH2 CELL; TREATMENT INDICATION;

ADAPTIVE IMMUNITY; ANIMALS; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; INFLAMMATION; NATRIURETIC PEPTIDES; PATENTS AS TOPIC; RECEPTORS, ATRIAL NATRIURETIC FACTOR;

EID: 77954062522     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221310791163125     Document Type: Article

References (164)

1. Gutkowska J, Nemer M. Structure, expression and function of atrial natriuretic factor in extraatrial tissues. Endocr Rev 1989; 10: 519-36.
2. Vollmar AM, Friedrich A, Sinowatz F, Schulz R. Presence of atrial natriuretic peptide-like material in guinea pig intestine. Peptides 1988; 9: 965-71.
3. Agui T, Xin X, Cai Y, Shim G, Muramatsu Y, Yamada T, et al. Opposite actions of transforming growth factor-beta 1 on the gene expression of atrial natriuretic peptide biological and clearance receptors in a murine thymic stromal cell line. J Biochem 1995; 118: 500-7.
4. Baldini PM, De Vito P, Martino A, Fraziano M, Grimaldi C, Luly P, et al. Differential sensitivity of human monocytes and macrophages to ANP: A role of intracellular pH on reactive oxygen species production through the phospholipase involvement. J Leukoc Biol 2003; 73, 502-10.
5. Heim JM, Knau B, Sturm C, Fricke H, Hartmann J, Pachmann K, et al. Particulate ANP-sensitive guanylyl cyclase: Induction in cultured human peripheral CD3+ mononuclear blood cells. J Mol Med 1996; 74: 629-35.
6. Kiemer AK, Vollmar AM. Effects of different natriuretic peptides on nitric oxide synthesis in macrophages. Endocrinology 1997; 138: 4282-90.
7. Sprenger H, Beck J, Nain M, Wesemann W, Gemsa D. The lack of receptors for atrial natriuretic peptides on human monocytes prevents a rise of cGMP and induction of tumor necrosis factoralpha synthesis. Immunobiology 1991; 183: 94-101.
8. Throsby M, Lee D, Huang WQ, Yang ZY, Copolov DL, Lim AT. Evidence for atrial natriuretic peptide-(5-28) production by macrophages of the rat spleen: An immunochemical and nonradioactive in situ hybridization approach. Endocrinology 1991; 129: 991-1000.
9. Vollmar AM, Colbatzky F, Schulz R. Expression of atrial natriuretic peptide in thymic macrophages after dexamethasone treatment of rats. Cell Tissue Res 1992; 268; 397-9.
10. Vollmar AM, Colbatzky F, Schulz R. Increased production of atrial natriuretic peptide in the rat thymus after irradiation. Immunopharmacology 1993; 26: 65-72.
11. Vollmar AM, Lang RE, Hanze J, Schulz R. The rat thymus-a site of atrial natriuretic peptide synthesis. Peptides 1990; 11: 33-7.
12. Vollmar AM, Schmidt KN, Schulz R. Natriuretic peptide receptors on rat thymocytes: inhibition of proliferation by atrial natriuretic peptide. Endocrinology 1996; 137: 1706-13.
13. Vollmar AM, Schulz R. Dexamethasone action on rat thymic atrial natriuretic peptide. Endocrinology1990; 127: 3240-2.
14. Vollmar AM, Schulz R. Expression and differential regulation of natriuretic peptides in mouse macrophages. J Clin Invest 1994; 94: 539-45.
15. Vollmar AM, Schulz R. Gene expression and secretion of atrial natriuretic peptide by murine macrophages. J Clin Invest 1995; 95: 2442-50.
16. Kisch B. Electronmicroscopy of the atrium of the heart. I. Guinea pig. Exp Med Surg 1956; 14: 99-112.
17. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. Rapid and potent natriuretic response to intravenous injection of atrial myocardial extracts in rats. Life Sci 1981; 28: 89-94.
18. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988; 332: 78-81.
19. Saito Y, Nakao K, Itoh H, Yamada T, Mukoyama M, Arai H, et al. Brain natriuretic peptide is a novel cardiac hormone. Biochem Biophys Res Commun 1989; 158: 360-68.
20. Sudoh T, Minamino N, Kangawa K, Matsuo H. A new natriuretic peptide in porcine brain. Biochem Biophys Res Commun 1990; 168: 863-70.
21. Schulz-Knappe P, Forssmann K, Herbst F, Hock D, Pipkorn R, Forssmann WG. Isolation and structural analysis of urodila-tin, a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin Wochenschr 1988; 66: 752-59.
22. Beltowski J. Guanylin and related peptides. J Physiol Pharmacol 2001; 52: 351-75.
23. Schweitz H, Vigne P, Moinier D, Frelin C, Lazdunski M. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J Biol Chem 1992; 267: 13928-32.
24. Schirger JA, Heublein DM, Chen HH, Lisy O, Jougasaki M, Wennberg PW, et al. Presence of Dendroaspis natriuretic peptidelike immunoreactivity in human plasma and its increase during human heart failure. Mayo Clin Proc 1999; 74: 126-30.
25. Koller KJ, Goeddel DV. Molecular biology of the natriuretic peptides and their receptors. Circulation 1992; 86: 1081-8.
26. Nakao K, Ogawa Y, Suga S, Imura H. Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors. J Hypertens 1992; 10: 1111-4.
27. Suga S, Nakao K, Hosoda K, Mukoyama M, Ogawa Y, Shirakami G, et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology 1992; 130: 229-39.
28. Anand-Srivastava MB. Natriuretic peptide receptor-C signaling and regulation. Peptides 2005; 26: 1044-59.
29. Cohen D, Koh GY, Nikonova LN, Porter JG, Maack T. Molecular determinants of the clearance function of type C receptors of natriuretic peptides. J Biol Chem 1996; 271: 9863-9.
30. Maack T, Suzuki M, Almeida FA, Nussenzveig D, Scarborough RM, McEnroe GA, et al. Physiological role of silent receptors of atrial natriuretic factor. Science 1987; 238: 675-8.
31. Klinger JR, Moalli R, Warburton RR, Wrenn DS, Hill NS. Creceptor ligand blocks pulmonary clearance of atrial natriuretic peptide in isolated rat lungs. Proc Soc Exp Biol Med 1992; 201: 154-8.
32. Sabbatini ME, Vatta MS, Vescina C, Gonzales S, Fernandez B, Bianciotti LG. C-type natriuretic peptide enhances amylase releasethrough NPR-C receptors in the exocrine pancreas. Regul Pept 2003; 116: 13-20.
33. Wilcox JN, Augustine A, Goeddel DV, Lowe DG. Differential regional expression of three natriuretic peptide receptor genes within primate tissues. Mol Cell Biol 1991; 11: 3454-62.
34. Charles CJ, Espiner EA, Nicholls MG, Richards AM, Yandle TG, Protter A, et al. Clearance receptors and endopeptidase 24.11: Equal role in natriuretic peptide metabolism in conscious sheep. Am J Physiol 1996; 271: R373-80.
35. Roques BP, Noble F, Dauge V, Fournie-Zaluski MC, Beaumont A. Neutral endopeptidase 24.11: Structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 1993; 45: 87-146.
36. Vollmar AM. Influence of atrial natriuretic peptide on thymocyte development in fetal thymic organ culture. J Neuroimmunol 1997; 78: 90-6.
37. Dempsey PW, Vaidya SA, Cheng G. The art of war: Innate and adaptive immune responses. Cell Mol Life Sci 2003; 60: 2604-21.
38. Kiemer AK, Vollmar AM. Autocrine regulation of inducible nitricoxide synthase in macrophages by atrial natriuretic peptide. J Biol Chem 1998; 273: 13444-51.
39. Kiemer AK, Vollmar AM. Induction of l-arginine transport is inhibited by atrial natriuretic peptide: A peptide hormone as a novel regulator of inducible nitric-oxide synthase substrate availability. Mol Pharmacol 2001; 60: 421-26.
40. Kiemer AK, Vollmar AM. Elevation of intracellular calcium levels contributes to the inhibition of nitric oxide production by atrial natriuretic peptide. Immunol Cell Biol 2001; 79: 11-7.
41. Kiemer AK, Hartung T, Vollmar AM. cGMP-mediated inhibition of TNF-alpha production by the atrial natriuretic peptide in murine macrophages. J Immunol 2000; 165: 175-81.
42. Kiemer AK, Vollmar AM, Bilzer M, Gerwig T, Gerbes AL. Atrial natriuretic peptide reduces expression of TNF-alpha mRNA during reperfusion of the rat liver upon decreased activation of NF-kappaB and AP-1. J Hepatol 2000; 33: 236-46.
43. Tsukagoshi H, Shimizu Y, Kawata T, Hisada T, Iwamae S, Ishizuka T, et al. Atrial natriuretic peptide inhibits tumor necrosis factor-alpha production by interferon-gamma-activated macrophages via suppression of p38 mitogen-activated protein kinase and nuclear factor-kappa B activation. Regul Pept 2001; 99: 21-9.
44. Vollmar AM, Forster R, Schulz R. Effects of atrial natriuretic peptide on phagocytosis and respiratory burst in murine macrophages. Eur J Pharmacol 1997; 319: 279-85.
45. Bilzer M, Jaeschke H, Vollmar AM, Paumgartner G, Gerbes AL. Prevention of Kupffer cell-induced oxidant injury in rat liver by atrial natriuretic peptide. Am J Physiol 1999; 276: G1137-44.
46. Mattana J, Singhal PC. Effects of atrial natriuretic peptide and cGMP on uptake of IgG complexes by macrophages. Am J Physiol 1993; 265: C92-8.
47. Kiemer AK, Weber NC, Furst R, Bildner N, Kulhanek-Heinze S, Vollmar AM. Inhibition of p38 MAPK activation via induction of MKP-1: Atrial natriuretic peptide reduces TNF-alpha-induced actin polymerization and endothelial permeability. Circ Res 2002; 90: 874-81.
48. Wiedermann CJ, Niedermuhlbichler M, Braunsteiner H, Widermann CJ. Priming of polymorphonuclear neutrophils by atrial natriuretic peptide in vitro. J Clin Invest 1992; 89: 1580-6.
49. Biselli R, Farrace S, De Simone C, Fattorossi A. Potentiation of human polymorphonuclear leukocyte activation by atrial natriuretic peptide. inhibitory effect of carnitine congeners. Inflammation 1996; 20: 33-42.
50. Moss RB, Golightly MG. in vitro Enhancement of natural cytotoxicity by atrial natriuretic peptide fragment 4-28. Peptides 1991; 12: 851-4.
51. Poredos P. Endothelial dysfunction in the pathogenesis of atherosclerosis. Clin Appl Thromb Hemost 2001; 7: 276-80.
52. Volk T, Kox WJ. Endothelium function in sepsis. Inflamm Res 2000; 49: 185-98.
53. Ten Hagen TL, Seynhaeve AL, Eggermont AM. Tumor necrosis factor-mediated interaction between inflammatory response and vascular bed. Immunol Rev 2008; 222: 299-15.
54. Baron D A, Lofton CE, Newman WH, Currie MG. Atriopeptin inhibition of thrombin-mediated changes in the morphology and permeability of endothelial monolayers. Proc Natl Acad Sci USA 1989; 86: 3394-8.
55. Pedram A, Razandi M, Levin ER. Natriuretic peptides suppress vascular endothelial cell growth factor signaling to angiogenesis. J Biol Chem 2002; 277: 44385-98.
56. Furst R, Bubik MF, Bihari P, Mayer BA, Khandoga AG, Hoffmann F, et al. Atrial natriuretic peptide induces mitogen-activated protein kinase phosphatase-1 in human endothelial cells via Rac1 and NAD(P)H oxidase-2 activation. Mol Pharmacol 2008; 74: 1-8.
57. Kiemer AK, Weber NC, Vollmar AM. Induction of IkappaB: Atrial natriuretic peptide as a regulator of the NF-kappaB pathway. Biochem Biophys Res Commun 2002; 295: 1068-76.
58. Weber NC, Blumenthal SB, Hartung T, Vollmar AM, Kiemer A. K. ANP inhibits TNF-alpha-induced endothelial MCP-1 expression-involvement of p38 MAPK and MKP-1. J Leukoc Biol 2003; 74: 932-41.
59. Matsumura T, Kugiyama K, Sugiyama S, Ohgushi M, Amanaka K, Suzuki M, et al. Neutral endopeptidase 24.11 in neutrophils modulates protective effects of natriuretic pep. J Clin Invest 1996; 97: 2192-203.
60. Harlan JM, Killen PD, Harker LA, Striker GE, Wright DG. Neutrophil-mediated endothelial injury in vitro mechanisms of cell detachment. J Clin Invest 1981; 68: 1394-403.
61. Inauen W, Granger DN, Meininger CJ, Schelling ME, Granger HJ, Kvietys PR. Anoxia-reoxygenation-induced, neutrophil-mediated endothelial cell injury: Role of elastase. Am J Physiol 1990; 259: H925-31.
62. Lum H, Gibbs L, Lai L, Malik AB. CD18 integrin-dependent endothelial injury: Effects of opsonized zymosan and phorbol ester activation. J Leukoc Biol 1994; 55: 58-63.
63. Woodman RC, Reinhardt PH, Kanwar S, Johnston FL, Kubes P. Effects of human neutrophil elastase (HNE) on neutrophil function in vitro and in inflamed microvessels. Blood 1993; 82: 2188-95.
64. Sugiyama S, Kugiyama K, Ohgushi M, Fujimoto K, Yasue H. Lysophosphatidylcholine in oxidized low-density lipoprotein increases endothelial susceptibility to polymorphonuclear leukocyte-induced endothelial dysfunction in porcine coronary arteries. Circ Res 1994; 74: 565-75.
65. Elferink JG, VanUffelen BE. The role of cyclic nucleotides in neutrophil migration. Gen Pharmacol 1996; 27: 387-93.
66. Ladetzki-Baehs K, Keller M, Kiemer AK, Koch E, Zahler S, Wendel A, et al. Atrial natriuretic peptide, a regulator of nuclear factor-{kappa}b activation in vivo. Endocrinology 2007; 148: 332-6.
67. Kiemer AK, Bildner N, Weber NC, Vollmar AM. Characterization of heme oxygenase 1 (heat shock protein 32) induction by atrial natriuretic peptide in human endothelial cells. Endocrinology 2003; 144: 802-12.
68. Mitaka C, Hirata Y, Nagura T, Tsunoda Y, Amaha K. Injury peptide on pulmonary gas exchange in beneficial. Chest 1998; 114: 223-8.
69. Mehta J, Dinerman J, Mehta P, Saldeen TG, Lawson D, Donnelly WH, et al. Neutrophil function in ischemic heart disease. Circulation 1989; 79: 549-56.
70. Tsao PS, Aoki N, Lefer DJ, Johnson G, Lefer AM. Time course of endothelial dysfunction and myocardial injury during myocardial ischemia and reperfusion in the cat. Circulation 1990; 82: 1402-12.
71. Izumi T, Saito Y, Kishimoto I, Harada M, Kuwahara K, Hamanaka I, et al. Blockade of the natriuretic peptide receptor guanylyl cyclase-A inhibits NF-kappaB activation and alleviates myocardial ischemia/reperfusion injury. J Clin Invest 2001; 108: 203-13.
72. Verma S, Fedak PW, Weisel RD, Butany J, Rao V, Maitland A, et al. Fundamentals of reperfusion injury for the clinical cardiologist. Circulation 2002; 105: 2332-36.
73. Mtairagel M, Houard X, Rais S, Pasquier C, Oudghiri M, Jacob MP, et al. Pharmacological potentiation of natriuretic peptide limits polymorphonuclear neutrophil-vascular cell interactions. Arterioscler Thromb Vasc Biol 2002; 22: 1824-31.
74. Koh KK, Oh PC, Quon MJ. Does reversal of oxidative stress and inflammation provide vascular protection? Cardiovasc Res 2009; 81: 649-59.
75. Shono M, Yoshimura M, Nakayama M, Yamamuro M, Abe K, Suzuki S, et al. Predominant effect of A-type natriuretic peptide on reduction of oxidative stress during the treatment of patients with heart failure. Circ J 2007; 71: 1040-46.
76. Laskowski A, Woodman OL, Cao AH, Drummond GR, Marshall T, Kaye DM, et al. Antioxidant actions contribute to the antihypertrophic effects of atrial natriuretic peptide in neonatal rat cardiomyocytes. Cardiovasc Res 2006; 72: 112-23.
77. Gerbes AL, Vollmar AM, Kiemer AK, Bilzer M. The guanylate cyclase-coupled natriuretic peptide receptor: A new target for prevention of cold ischemia-reperfusion damage of the rat liver. Hepatology 1998; 28: 1309-17.
78. Dai YS, Cserjesi P, Markham BE, Molkentin JD. The transcription factors GATA4 and dHAND physically interact to synergistically activate cardiac gene expression through a p300-dependent mechanism. J Biol Chem 2002; 277: 24390-98.
79. Temsah R, Nemer M. GATA factors and transcriptional regulation of cardiac natriuretic peptide genes. Regul Pept 2005; 128: 177-85.
80. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767-11.
81. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002; 20: 621-67.
82. Kalinski P, Hilkens CM, Snijders A, Snijdewint FG, Kapsenberg ML. IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J Immunol 1997; 159: 28-35.
83. Mazzoni A, Young HA, Spitzer JH, Visintin A, Segal DM. Histamine regulates cytokine production in maturing dendritic cells, resulting in altered T cell polarization. J Clin Invest 2001; 108: 1865-73.
84. Penna G, Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000; 164: 2405-11.
85. Piemonti L, Monti P, Sironi M, Fraticelli P, Leone BE, Dal Cin E, et al. Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol 2000; 164: 4443-51.
86. Vieira PL, Kalinski P, Wierenga EA, Kapsenberg ML, de Jong E C. Glucocorticoids inhibit bioactive IL-12 p70 production by in vitro generated human dendritic cells without affecting their T cell stimulatory potential. J Immunol 1998; 161: 5245-51.
87. Morita R, Fujita T, Uchiyama T, Hori T. Human plasmacytoid dendritic cells express an atrial natriuretic peptide receptor, guanylyl cyclase-A. Microbiol Immunol 2009; 53: 403-11.
88. Morita R, Ukyo N, Furuya M, Uchiyama T, Hori T. Atrial natriuretic peptide polarizes human dendritic cells toward a Th2-promoting phenotype through its receptor guanylyl cyclase-coupled receptor A. J Immunol 2003; 170: 5869-75.
89. Hori, T. Medicinal composition for preventing or treating TH1 type immunological disease. EP1637162 (2006).
90. Akbari O, Stock P, Meyer E, Kronenberg M, Sidobre S, Nakayama T, et al. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat Med 2003; 9: 582-8.
91. Saetta M, Turato G. Airway pathology in asthma. Eur Respir J 2001, 34 (Suppl): 18s-23s.
92. Chai OH, Lee YH, Han EH, Kim HT, Lee MS, Song CH. Atrial natriuretic peptide induces rat peritoreal mast cell activation by cGMP-independent and calcium-dependant mechanism. Exp Mol Med 2000; 32: 179-86.
93. Szukiewicz D, Maslinska D, Szukiewicz A, Zaczek R, Szewczyk G, Stelmachow J, et al. The dose-dependent release of histamine form placental mast cells after administration of atrial natriuretic peptide. Inflamm Res 2001; 50 (Suppl 2): S59-60.
94. Sharara AM, Higham MA, Spanevello A, Ind PW. Effects of intradermal injection of atrial natriuretic peptide. Br J Clin Pharmacol 1995; 40: 283-5.
95. Opgenorth TJ, Budzik GP, Mollison KW, Davidsen SK, Holst M R, Holleman WH. Atrial peptides induce mast cell histamine release. Peptides 1990; 11: 1003-7.
96. Yoshida H, Inagaki Y, Yamaki K, Beppu Y, Kawashima T, Takagi K. Histamine relase induced by human natriuretic peptide from rat peritoneal mast cells. Regul Pept 1996; 61: 45-49.
97. Murray DB, Gardner JD, Levick SP, Brower GL, Morgan LG, Janicki JS. Response of cardiac mast cells to atrial natriuretic peptide. Am J Physiol Heart Circ Physiol 2007; 293: H1216-22.
98. Hulks G, Jardine AG, Connell JM, Thomson NC. Influence of elevated plasma levels of atrial natriuretic factor on bronchial reactivity in asthma. Am Rev Respir Dis 1991; 143: 778-82.
99. Mohapatra SS, Lockey RF, Vesely DL, Gower WR. Natriuretic peptides and genesis of asthma: An emerging paradigm? J Allergy Clin Immunol 2004; 114: 520-26.
100. Wang X, Xu W, Mohapatra S, Kong X, Li X, Lockey RF, et al. Prevention of airway inflammation with topical cream containing imiquimod and small interfering RNA for natriuretic peptide receptor. Genet Vaccines Ther 2008; 6: 7.
101. Mohapatra, S. S. Materials and methods for treatment of allergic diseases. US20060276382 (2006).
102. Sharif, N. A., Katoli, P. Use of natriuretic peptide receptor antagonists to treat ocular, otic and nasal edemetous conditions. US20070225225 (2007).
103. Ohbayashi H, Suito H, Takagi K. Compared effects of natriuretic peptides on ovalbumin-induced asthmatic model. Eur J Pharmacol 1998; 346: 55-64.
104. Devillier P, Corompt E, Breant D, Caron F, Bessard G. Relaxation and modulation of cyclic AMP production in response to atrial natriuretic peptides in guinea pig tracheal smooth muscle. Eur J Pharmacol 2001; 430: 325-33.
105. Angus RM, McCallum MJ, Hulks G, Thomson NC. Bronchodilator, cardiovascular, and cyclic guanylyl monophosphate response to high-dose infused atrial natriuretic peptide in asthma. Am Rev Respir Dis 1993; 147: 1122-25.
106. Lindberg F, Andersson KE. Vasodilator responses to alpha-humanatrial natriuretic peptide in isolated omental and pulmonary arteries from rabbit and man. Acta Physiol Scand 1988; 134: 391-7.
107. Angus RM, McCallum MJ, Thomson NC. Effect of inhaled atrial natriuretic peptide on methacholine induced bronchoconstriction in asthma. Clin Exp Allergy 1994; 24: 784-8.
108. Angus RM, Millar EA, Chalmers GW, Thomson NC. Effect of inhaled atrial natriuretic peptide and a neutral endopeptidase inhibitor on histamine-induced bronchoconstriction. Am J Respir Crit Care Med 1995; 151: 2003-5.
109. Mizuguchi M, Myo S, Fujimura M. Bronchoprotective effects of atrial natriuretic peptide against propranolol-induced bronchoconstriction after allergic reaction in guinea pigs. Clin Exp Allergy 2000; 30: 439-44.
110. McAlpine LG, Hulks G, Thomson NC. Effect of atrial natriuretic peptide given by intravenous infusion on bronchoconstriction induced by ultrasonically nebulized distilled water (fog). Am Rev Respir Dis 1992; 146: 912-5.
111. Biollaz J, Callahan LT, Nussberger J, Waeber B, Gomez HJ, Blaine EH, et al. Pharmacokinetics of synthetic atrial natriuretic peptides in normal men. Clin Pharmacol Ther 1987; 41: 671-7.
112. Mohapatra, S. S., Xu, W., Kong, X., Wang, X. Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor. US20070265204 (2007).
113. Hellermann G, Kong X, Gunnarsdottir J, San Juan H, Singam R, Behera S, et al. Mechanism of bronchoprotective effects of a novel natriuretic hormone peptide. J Allergy Clin Immunol 2004; 113: 79-85.
114. Wang X, Xu W, Kong X, Chen D, Hellermann G, Ahlert TA, et al. Modulation of lung inflammation by vessel dilator in a mouse model of allergic asthma. Respir Res 2009; 10: 66.
115. Vesely, D. L. Oral methods of treatment using proANF peptides. US20060205642 (2006).
116. Masters RG, Davies RA, Veinot JP, Hendry PJ, Smith SJ. Discoordinate modulation of natriuretic peptides during acute cardiac allograft rejection in humans. Circulation 1999; 100: 287-91.
117. He Q, LaPointe MC. Interleukin-1beta regulation of the human brain natriuretic peptide promoter involves Ras-, Rac-, and p38 kinase-dependent pathways in cardiac myocytes. Hypertension 1999; 33: 283-9.
118. Harada E, Nakagawa O, Yoshimura M, Harada M, Nakagawa M, Mizuno Y, et al. Effect of interleukin-1 beta on cardiac hypertrophy and production of natriuretic peptides in rat cardiocyte culture. J Mol Cell Cardiol 1999; 31: 1997-2006.
119. Ma KK, Ogawa T, de Bold AJ. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J Mol Cell Cardiol 2004; 36: 505-13.
120. Tanaka T, Kanda T, Itoh T, Tsugawa H, Takekoshi N, Yamakawa J, et al. Increased cardiac weight in interleukin-6 transgenic mice with viral infection accompanies impaired expression of natriuretic peptide genes. Res Commun Mol Pathol Pharmacol 2001; 110: 275-83.
121. Vesely DL, de Bold AJ. Cardiac natriuretic peptides gene expression and secretion in inflammation. J Investig Med 2009; 57: 29-32.
122. Bruggink AH, de Jonge N, van Oosterhout MF, Van Wichen DF, de Koning E, Lahpor JR, et al. Brain natriuretic peptide is produced both by cardiomyocytes and cells infiltrating the heart in patients with severe heart failure supported by a left ventricular assist device. J Heart Lung Transplant 2006; 25: 174-80.
123. Chiurchiu V, Izzi V, D'Aquilio F, Carotenuto F, Di Nardo P, Baldini PM. Brain natriuretic peptide (BNP) regulates the production of inflammatory mediators in human THP-1 macrophages. Regul Pept 2008; 148: 26-32.
124. Shaw SM, Fildes JE, Puchalka CM, Basith M, Yonan N, Williams SG. BNP directly immunoregulates the innate immune system of cardiac transplant recipients in vitro. Transpl Immunol 2009; 20: 199-202.
125. Nikolaou NI, Goritsas C, Dede M, Paissios NP, Papavasileiou M, Rombola AT, et al. Brain natriuretic peptide increases in septic patients without severe sepsis or shock. Eur J Intern Med 2007; 18: 535-41.
126. Shor R, Rozenman Y, Bolshinsky A, Harpaz D, Tilis Y, Matas Z, et al. BNP in septic patients without systolic myocardial dysfunction. Eur J Intern Med 2006; 17: 536-40.
127. Hung J, Lew WY. Cellular mechanisms of endotoxin-induced myocardial depression in rabbits. Circ Res 1993; 73: 125-34.
128. Tomaru Ki K, Arai M, Yokoyama T, Aihara Y, Sekiguchi Ki K, Tanaka T, et al. Transcriptional activation of BNP gene by lipopolysaccharide is mediated through GATA element in neonatal rat cardiac myoctyes. J Mol Cell Cardiol 2002; 34: 649-59.
129. Vila G, Resl M, Stelzeneder D, Struck J, Maier C, Riedl M, et al. Plasma NT-proBNP increases in response to LPS administration in healthy men J Appl Physiol 2008; 105: 1741-45.
130. Komatsu Y, Itoh H, Suga S, Ogawa Y, Hama N, Kishimoto I, et al. Regulation of endothelial production of C-type natriuretic peptide in coculture with vascular smooth muscle cells. Role of the vascular natriuretic peptide system in vascular growth inhibition. Circ Res 1996; 78: 606-14.
131. Hama N, Itoh H, Shirakami G, Suga S, Komatsu Y, Yoshimasa T, et al. Detection of C-type natriuretic peptide in human circulation and marked increase of plasma CNP level in septic shock patients. Biochem Biophys Res Commun 1994; 198: 1177-82.
132. Zhang LM, Castresana MR, McDonald MH, Johnson JH, Newman WH. Response of human artery, vein, and cultured smooth muscle cells to atrial and C-type natriuretic peptides. Crit Care Med 1996; 24: 306-10.
133. Suga S, Itoh H, Komatsu Y, Ogawa Y, Hama N, Yoshimasa T, et al. Cytokine-induced C-type natriuretic peptide (CNP) secretion from vascular endothelial cells--evidence for CNP as a novel autocrine/paracrine regulator from endothelial cells. Endocrinology 1993; 133: 3038-41.
134. Kiemer AK, Lehner MD, Hartung T, Vollmar AM. Inhibition of cyclooxygenase-2 by natriuretic peptides. Endocrinology 2002; 143: 846-52.
135. Chun TH, Itoh H, Saito T, Yamahara K, Doi K, Mori Y, et al. Oxidative stress augments secretion of endothelium-derived relaxing peptides, C-type natriuretic peptide and adrenomedullin. J Hypertens 2000; 18: 575-80.
136. Schachner T, Zou Y, Oberhuber A, Mairinger T, Tzankov A, Laufer G, et al. Perivascular application of C-type natriuretic peptide attenuates neointimal hyperplasia in experimental vein grafts. Eur J Cardiothorac Surg 2004; 25: 585-90.
137. Ohno N, Itoh H, Ikeda T, Ueyama K, Yamahara K, Doi K, et al. Accelerated reendothelialization with suppressed thrombogenic property and neointimal hyperplasia of rabbit jugular vein grafts by adenovirus-mediated gene transfer of C-type natriuretic peptide. Circulation 2002; 105: 1623-6.
138. Hobbs, A, Foster P, Prescott C, Scotland R, Ahluwalia A. Natriuretic peptide receptor-c regulates coronary blood flow and prevents myocardial ischemia/reperfusion injury. Circulation 2004; 110: 1231-5.
139. Naruko T, Ueda M, van der Wal AC, van der Loos CM, Itoh H, Nakao K, et al. C-type natriuretic peptide in human coronary atherosclerotic lesions. Circulation 1996; 94: 3103-8.
140. Scotland RS, Cohen M, Foster P, Lovell M, Mathur A, Ahluwalia A, et al. C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression. Proc Natl Acad Sci USA 2005; 102: 14452-7.
141. Obata H, Yanagawa B, Tanaka K, Ohnishi S, Kataoka M, Miyahara Y, et al. CNP infusion attenuates cardiac dysfunction and inflammation in myocarditis. Biochem Biophys Res Commun 2007; 356: 60-6.
142. Murakami S, Nagaya N, Itoh T, Fujii T, Iwase T, Hamada K, et al. C-type natriuretic peptide attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 2004; 287: L1172-7.
143. Balabanian K, Foussat A, Dorfmuller P, Durand-Gasselin I, Capel F, Bouchet-Delbos L, et al. CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165: 1419-25.
144. Dorfmuller P, Zarka V, Durand-Gasselin I, Monti G, Balabanian K, Garcia G, et al. Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165: 534-9.
145. Tuder RM, Voelkel NF. Pulmonary hypertension and inflammation. J Lab Clin Med 1998; 132: 16-24.
146. Kimura H, Kasahara Y, Kurosu K, Sugito K, Takiguchi Y, Terai M, et al. Alleviation of monocrotaline-induced pulmonary hypertension by antibodies to monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. Lab Invest 1998; 78: 571-81.
147. Sugita T, Hyers TM, Dauber IM, Wagner WW, McMurtry IF, Reeves JT. Lung vessel leak precedes right ventricular hypertrophy in monocrotaline-treated rats. J Appl Physiol 1983; 54: 371-4.
148. Itoh T, Nagaya N, Murakami S, Fujii T, Iwase T, Ishibashi-Ueda H, et al. C-type natriuretic peptide ameliorates monocrotalineinduced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004; 170: 1204-11.
149. Shailubhai, K., Jacob, G.S. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders. US20090048175 (2009).
150. Fluge T, Forssmann WG, Kunkel G, Schneider B, Mentz P, Forssmann K, et al. Bronchodilation using combined urodilatin -albuterol administration in asthma: a randomized, double-blind, placebo-controlled trial. Eur J Med Res 1999; 4: 411-5.
151. Fluge, T., Forssmann, W.-G. Use of urodilatin in pulmonary and bronchial diseases. US5571789 (1996).
152. James, K. D., Radhakrishnan, B., Malkar, N.B., Miller, M.A., Ekwuribe, N.N. Natriuretic compounds, conjugates, and uses thereof. US20060172933 (2006).
153. Cataliotti A, Schirger JA, Martin FL, Chen HH, McKie PM, Boerrigter G, et al. Oral human brain natriuretic peptide activates cyclic guanosine 3′,5′-monophosphate and decreases mean arterial pressure. Circulation 2005; 112: 836-40.
154. Rosen, C. A., Haseltine, W.A. Albumin fusion proteins. US6926898 (2005).
155. Wang W, Ou Y, Shi Y. AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure. Pharm Res 2004; 21: 2105-11.
156. Young, M. K., Dae, J.K., Sung, M.B., Chang, K.L., Se, C.K., Gwan, S.L., Dae, H.S., Young, H.K. Natriuretic peptide conjugate using carrier substance. US20080085862 (2008).
157. Maa, Y. K., Sellars, S., Daddona, P., Kamberi, M., Gopalakrishnan, V., Silber, M., Stonebanks, F. Apparatus and method for transdermal delivery of natriuretic peptides. US20060034903 (2006).
158. Trapani AJ, Smits GJ, McGraw DE, Spear KL, Koepke JP, Olins GM, et al. Thiorphan, an inhibitor of endopeptidase 24.11, potentiates the natriuretic activity of atrial natriuretic peptide. J Cardiovasc Pharmacol 1989; 14: 419-24.
159. Barnes PJ. Neurogenic inflammation in the airways. Respir Physiol 2001; 125: 145-54.
160. Hodgson-Zingman DM, Karst ML, Zingman LV, Heublein DM, Darbar D, Herron KJ, et al. Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. N Engl J Med 2008; 359: 158-65.
161. Pan S, Chen HH, Dickey DM, Boerrigter G, Lee C, Kleppe LS, et al. Vascular-directed tissue factor pathway inhibitor overexpression regulates plasma cholesterol and reduces atherosclerotic plaque development. Proc Natl Acad Sci USA 2009; 106: 11282-7.
162. Simari, R. D. Adenovirus vectors encoding brain natriuretic peptide. US20060025367 (2006).
163. Burnett, J.C.J., Lisy, O. Chimeric natriuretic peptides. US7384917 (2008).
164. Moro C, Klimcakova E, Lolmede K, Berlan M, Lafontan M, Stich V, et al. Atrial natriuretic peptide inhibits the production of adipokines and cytokines linked to inflammation and insulin resistance in human subcutaneous adipose tissue. Diabetologia 2007; 50: 1038-47.